Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: A cross-sectional comparative study

Scandinavian Journal of Rheumatology

Volumn 44, Issue 2, 2015, Pages 118-124

  Sveaas, S H ^a   Berg, I J ^b   Provan, S A ^b   Semb, A G ^b   Olsen, I C ^b   Ueland, T ^b,c   Aukrust, P ^b,c   Vollestad, N ^a   Hagen, K B ^a   Kvien, T K ^b   Dagfinrud, H ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR 1; BIOLOGICAL MARKER; CYTOKINE; CYTOKINE RECEPTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-23; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RECEPTORS, CYTOKINE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 84924406874     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.956142     Document Type: Article

References (38)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
2. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2013;73:6-16.
3. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006;65:713-20.
4. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
5. Appel H, Maier R, Bleil J, Hempfing A, Loddenkemper C, Schlichting U, et al. In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013;65:1522-9.
6. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
7. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-15.
8. Park MC, Lee SW, Choi ST, Park YB, Lee SK. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 2007;36:101-6.
9. Pedersen SJ, Hetland ML, Sorensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol 2010;29:1301-9.
10. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 2011;30:269-73.
11. Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009;29:1343-7.
12. Li GX, Wang S, Duan ZH, Zeng Z, Pan FM. Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol 2013;42:226-31.
13. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1705-13.
14. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1378-87.
15. Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014;73:817-23.
16. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
17. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-18.
18. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol 2014;57:28-37.
19. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
20. Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 2010;29:1155-61.
21. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6.
22. Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 2012;32:2523-7.
23. Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 2006; 45:1197-200.
24. Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 2012;13:191.
25. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
26. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009;29:975-80.
27. Mogelvang R, Haahr-Pedersen S, Bjerre M, Frystyk J, Iversen A, Galatius S, et al. Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013; 99:106-10.
28. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:557-63.
29. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5.
30. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012;18:1069-76.
31. Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011;70:1275-81.
32. Falkenbach A, Herold M. In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changesin the variables for mobility. Rheumatol Int 1998;18:103-6.
33. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014;73:95-100.
34. Sari I, Kebapcilar L, Taylan A, Bilgir O, Kozaci DL, Yildiz Y, et al. Fetuin-A and interleukin-18 levels in ankylosing spondylitis. Int J Rheum Dis 2010;13:75-81.
35. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 2012;71:1207-11.
36. Machado P, Landewe RB, Braun J, Baraliakos X, Hermann KG, Hsu B, et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012;71:2002-5.
37. Weiss A, Song IH, Haibel H, Listing J, Sieper J. Good correlation between changes in objective and subjective signs of inflammation in short-but not long-diseased patients with axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Res Ther 2014;16:R35.
38. Sieper J, Poddubnyy D. Inflammation, new bone formation and treatment options in axial spondyloarthritis. Ann Rheum Dis 2014;73:1439-41.